Finance

Lists
500087:BOM
Cipla Ltd
₹1 414,95
-0,07%
(-1,05) 1D
20 Nov., 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 500087...
Open
₹1 419,20
High
₹1 428,00
Low
₹1 401,85
Mkt. cap
1,14 bn.
Avg. vol.
105,89 k
Volume
82,51 k
Dividend
0,92%
Quarterly dividend
₹3,25
Ex-dividend date
05 Jun. 2026
P/E ratio
39,49
52-wk high
₹1 539,25
52-wk low
₹1 165,55
EPS
₹35,83
Shares outstanding
805,67 m.
No. of employees
31 k
Open
₹1 419,20
High
₹1 428,00
Low
₹1 401,85
Mkt. cap
1,14 bn.
Avg. vol.
105,89 k
Volume
82,51 k
Dividend
0,92%
Quarterly dividend
₹3,25
Ex-dividend date
05 Jun. 2026
P/E ratio
39,49
52-wk high
₹1 539,25
52-wk low
₹1 165,55
EPS
₹35,83
Shares outstanding
805,67 m.
No. of employees
31 k
News stories
From web sources and news partners
Profile
Cipla Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Cipla primarily focuses on developing medication to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, paediatric and various other medical conditions. Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third-largest drug producer in India. Wikipedia
About Cipla Ltd
CEOUmang Vohra
Employees31,4 k
Founded1935
HeadquartersMumbai, Maharashtra, Indië
SectorHealth Care
IndustryPharmaceutical industry
Websitecipla.com
Last report
27 Okt. 2026
Fiscal period
Q2 2027
₹10,85 / ₹11,83
-8,28%miss
Revenue / Est. (INR)
73,68 mjd. / 75,88 mjd.
-2,90%miss
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Des. 2025
Mrt. 2026
Jun. 2026
Sep. 2026
Revenue
69,63 mjd.
65,80 mjd.
70,77 mjd.
73,68 mjd.
Cost of goods sold
26,32 mjd.
25,10 mjd.
26,67 mjd.
26,34 mjd.
Cost of revenue
26,32 mjd.
25,10 mjd.
26,67 mjd.
26,34 mjd.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13,25 mjd.
28,23 mjd.
14,97 mjd.
14,75 mjd.
Operating expense
33,54 mjd.
33,30 mjd.
35,22 mjd.
36,91 mjd.
Total operating expenses
59,86 mjd.
58,39 mjd.
61,89 mjd.
63,25 mjd.
Operating income
9,77 mjd.
7,41 mjd.
8,88 mjd.
10,43 mjd.
Other non operating income
2,06 mjd.
-5,35 mjd.
2,11 mjd.
1,51 mjd.
EBT including unusual items
8,93 mjd.
6,99 mjd.
10,80 mjd.
11,72 mjd.
EBT excluding unusual items
11,69 mjd.
4,51 mjd.
10,80 mjd.
11,72 mjd.
Income tax expense
2,19 mjd.
1,57 mjd.
2,95 mjd.
3,21 mjd.
Effective tax rate
24,48%
22,44%
27,29%
27,37%
Other operating expenses
17,51 mjd.
2,51 mjd.
17,20 mjd.
18,72 mjd.
Net income
6,76 mjd.
5,55 mjd.
7,89 mjd.
8,78 mjd.
Net profit margin
9,71%
8,43%
11,15%
11,91%
Earnings per share
10,94
6,86
9,76
10,85
Interest and investment income
-
2,07 mjd.
-
-
Interest expense
-140,30 m.
-69,70 m.
-170,30 m.
-167,40 m.
Net interest expenses
-140,30 m.
2,00 mjd.
-170,30 m.
-167,40 m.
Depreciation and amortization charges
2,78 mjd.
2,56 mjd.
3,04 mjd.
3,45 mjd.
EBITDA
12,00 mjd.
9,82 mjd.
11,29 mjd.
13,67 mjd.
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google-programme